(Alliance News) - Genedrive PLC on Friday reported a narrowed full-year loss as its net finance costs fell and revenue almost doubled from routine use of its MT-RNR1 test. Read More
Genedrive PLC - Manchester, England-based point-of-care pharmacogenetic testing company - Notes the presentation of two posters by authors from the NHS England Network of Excellence in Pharmacogenomics, the NHSE Genomics Unit, the NHSE National Stroke Programme, and the Manchester Centre for Genomic Medicine at the UK Stroke Forum in Aberdeen, Scotland. Says results included laboratory CYP2C19 testing and point-of-care rapid CYP2C19 genetic testing using the Genedrive CYP2C19 ID kit. Key findings included that "a higher prevalence of patients unlikely to respond to clopidogrel [was] identified in the near-patient arm", leading Genedrive to estimate that an additional roughly 4,200 per year stroke patients benefitting from alternative prescribing decisions could be identified using the CYP2C19 ID kit "due to its increased target coverage and ethnic inclusivity". Posters add: "Test results impacted prescription practices, guiding prescription changes and aligning treatment with patients' genetic profiles for better outcomes." Additionally: "Implementation of Genedrive CYP2C19 testing was feasible, scalable and effective in providing immediate availability of results during acute clinical settings. Moreover, the findings substantiate the clinical utility of CYP2C19 genotype-guided antiplatelet therapy in the management of patients with ischemic stroke or TIA, particularly with diverse British and European populations." Read More
Genedrive PLC - Manchester-based point-of-care pharmacogenetic testing company - says its MT-RNR1 ID kit will start being used for babies requiring antibiotic treatment for infections at the Royal Hospital for Children in Glasgow. The Royal Alexandra Hospital and Princess Royal Maternity Hospital are to follow soon after, as part of a phased rollout to all NHS Scotland Health Boards with neonatal units over the coming months. The company also notes recent media coverage about MT-RNR1 ID, which reduces the risk of deafness in newborn babies. Read More
Genedrive PLC - Manchester-based point-of-care pharmacogenetic testing company - Announces that its exclusive distribution partner in Saudi Arabia, iDeal iDea for Medical Equipment Technology, has signed a memorandum of understanding with Saudi Arabia's Ministry of Health. The MoU scope is to pilot Genedrive's MT-RNR1 ID Kit for potential national implementation under an initiative called "Generations Hear." Genedrive Chief Executive Officer Gino Miele says: "We are delighted with the signing of this MOU, which builds further on our commercial traction in Saudi Arabia and aligns perfectly to the long-term Saudi health goals. We are grateful to our valued partners at iDeal iDea for their support and look forward to progressing through pilot phase with the goal of implementation at national level." Read More
(Alliance News) - Genedrive PLC on Wednesday said its shareholders voted down its equity financing plan that would have extended its cash runway until the second or third quarter of next year, sending its shares higher in response. Read More
(Alliance News) - Genedrive PLC on Monday affirmed that an equity fundraise was the "only certain financing option available" and that it did not receive any expressions of M&A interest. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday. Read More
(Alliance News) - London stocks opened mostly lower on Wednesday, with defence firms in the green following US President Donald Trump's comments on the Ukraine-Russia war at the UN on Tuesday. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Genedrive PLC on Monday said it continues to assess its financing options after forecasting income in the financial year just ended would double from the year before. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Genedrive PLC on Wednesday announced follow-on funding of GBP200,000 for further improvements to user experiences in rapid genetic testing environments. Read More
(Alliance News) - Genedrive PLC on Thursday said it has conditionally raised GBP1.0 million via a subscription of new shares as it reported a wider loss in the first-half of its financial year. Read More
(Alliance News) - Genedrive PLC on Monday said the Scottish government will invest in two pharmacogenetic testing programmes using its kits. Read More
(Alliance News) - Genedrive PLC on Friday said its CYP2C19-ID genetic testing kit has shown superior performance compared to laboratory testing in a recently published clinical study. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday. Read More